Biotechnology
J&J Eyes Biotech Buyout to Strengthen Immunology Pipeline
Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases Johnson & Johnson (JNJ) is reportedly in active...
Envoy Medical Advances to Final Stage of FDA Trial for Fully Implanted Cochlear Implant
Positive early results accelerate timeline and reduce capital needs by up to $15 million Envoy Medical (COCH), a Minnesota-based hearing...
Drugmakers Gain as Markets Digest Trump’s Proposed 100% Pharma Tariffs
Exemptions for U.S. plant construction and existing expansion plans temper immediate fallout, but uncertainty remains for smaller firms Shares of...
Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast
Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...
ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug
PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences...
Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025
Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...
KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets
$710 Million Raised as David Bailey Leads Ambitious Plan to Transform Bitcoin Adoption Through Public Equity In a landmark move...
Hims & Hers Health Doubles Revenue in Q1 2025, Raises Full-Year Outlook
Surging subscriber growth and profitability prompt ambitious long-term targets for 2030 Hims & Hers Health, Inc. (HIMS), a leading digital...
Novo Nordisk Expands Wegovy Access Through Telehealth Providers
Partnership with Hims & Hers, Ro, and LifeMD aims to capture patients as compounded versions disappear Novo Nordisk (NVO) is...
Biotech Stocks Slide as FDA’s Peter Marks Resigns
Wall Street Reacts to Leadership Uncertainty in Biopharma Approvals The resignation of Peter Marks, director of the FDA’s Center for...
